Nathan Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of minimal residual disease (MRD) as a biomarker for lymphoma. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Dr Fowler gives an overview of current trials looking at circulating tumor DNA show promising results as circulating tumor DNA can monitor patients disease and predict the likelihood of relapse before it occurs. He emphasizes that MRD markers could largely impact a patients course of therapy whilst acting as an alternative to scans and reducing the risk of radiation as patients go through surveillance.
The impact of MRD as a biomarker
